Roche turns to DM to boost patient compliance with its weight loss drug.
It can be tough getting patients to take their medicines as prescribed, particularly when there are side-effects or other barriers involved. To get around this problem, Roche decided to develop a DM approach to guide patients taking the organization's new weight-loss agent, XENICAL. In place now for 15 months, the telephonic program is boosting compliance and getting the intended results.
D019440:Anti-Obesity Agents / Q000008:administration & dosage*; D003376:Counseling; D019468:Disease Management; D004345:Drug Industry; D006801:Humans; D007783:Lactones / Q000008:administration & dosage*; D009765:Obesity / Q000188:drug therapy*; D000077403:Orlistat; D010349:Patient Compliance; D010353:Patient Education as Topic; D012051:Reimbursement Mechanisms; D012646:Self Administration; D012944:Social Support; D013689:Telephone
D019440:Anti-Obesity Agents; D007783:Lactones; D000077403:Orlistat